Full Press Release Details
IceCure's ProSense Featured at CIRSE
2025 Annual Meeting: Positive Clinical Results with Cryoablation from 4 Independent Studies Presented
Presentations from 5 Key Opinion Leaders
on ProSense cryoablation including 3 independent studies on breast cancer and 1 on endometriosis
3 hands-on training sessions for doctors
interested in using ProSense were very well attended
Dedicated CIRSE focus session on the breast
shows the growing interest from interventional radiologists to expand their practice to include care for breast cancer patients
CAESAREA, Israel, September 22, 2025 - IceCure Medical
Ltd. (Nasdaq: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive
cryoablation technology that destroys tumors by freezing as an option to surgical tumor removal, today announced its participation at
the Cardiovascular and Interventional Radiology Society of Europe (CIRSE) Annual Meeting on September 13-17, 2025, in Barcelona, Spain.
The Company hosted a large number of medical practitioners interested in ProSense at its booth. Booth visitors experienced live demonstrations
and learned about how ProSense , a single-cryoprobe liquid nitrogen ("LN2") based cryoablation technology is shaping the
future of interventional oncology, especially for breast cancer patients.
"We had a very successful participation at CIRSE this year, as
ProSense offers what we believe is the most advanced clinically proven LN2 cryoablation system to the growing number of interventional
radiologists looking to grow their practice in breast care," stated IceCure's Chief Executive Officer, Eyal Shamir. "As
always, we truly appreciate the medical doctors who have conducted their own investigator-initiated studies of ProSense and who continue
to actively share their findings and positive experiences with their colleagues at these important medical conferences."
ProSense was featured in the following:
The ProSense Cryoablation System provides a minimally invasive
treatment option to destroy tumors by freezing them. The system uniquely harnesses the power of liquid nitrogen to create large lethal
zones for maximum efficacy in tumor destruction in benign and cancerous lesions, including breast, kidney, lung, and liver.
ProSense enhances patient and provider value by accelerating recovery,
reducing pain, surgical risks, and complications. With its easy, transportable design and liquid nitrogen utilization, ProSense opens
that door to fast and convenient office-based procedures for breast tumors.
About IceCure Medical
IceCure Medical (Nasdaq: ICCM) develops and markets
advanced liquid-nitrogen-based cryoablation therapy systems for the destruction of tumors (benign and cancerous) by freezing, with the
primary focus areas being breast, kidney, bone and lung cancer. Its minimally invasive technology is a safe and effective alternative
to hospital surgical tumor removal that is easily performed in a relatively short procedure. The Company's flagship ProSense system
is marketed and sold worldwide for the indications cleared and approved to date including in the U.S., Europe and Asia.
This press release contains forward-looking statements within the meaning of the "safe harbor" provisions
of the Private Securities Litigation Reform Act of 1995 and other Federal securities laws. Words such as "expects," "anticipates,"
"intends," "plans," "believes," "seeks," "estimates" and similar expressions or variations
of such words are intended to identify forward-looking statements. For example, IceCure is using forward looking statements
in this press release when it discusses the belief that ProSense offers the most advanced clinically proven LN2 cryoablation system.
Historical results of scientific research and clinical and preclinical trials do not guarantee that the conclusions of future research
or trials will suggest identical or even similar conclusions. Important factors that could cause actual results, developments and business
decisions to differ materially from those anticipated in these forward-looking statements include, among others: the Company's planned
level of revenues and capital expenditures; the Company's available cash and its ability to obtain additional funding; the Company's
ability to market and sell its products; legal and regulatory developments in the United States and other countries; the Company's
ability to maintain its relationships with suppliers, distributors and other partners; the Company's ability to maintain or protect the
validity of its patents and other intellectual property; the Company's ability to expose and educate medical professionals about its
products; political, economic and military instability in the Middle East, specifically in Israel; as well as those factors
set forth in the Risk Factors section of the Company's Annual Report on Form 20-F for the year ended December 31, 2024 filed
with the SEC on March 27, 2025, and other documents filed with or furnished to the SEC which are available on the SEC's website, www.sec.gov.
The Company undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required